Sorafenib Continuation after First Disease Progression Could Reduce Disease Flares and Provide Survival Benefits in Patients with Hepatocellular Carcinoma: a Pilot Retrospective Study |
Fu, Si-Rui
(Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences)
Zhang, Ying-Qiang (Department of Interventional Oncology, The First Affiliate Hospital, Sun Yat-Sen University) Li, Yong (Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences) Hu, Bao-Shan (Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences) He, Xu (Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences) Huang, Jian-Wen (Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences) Zhan, Mei-Xiao (Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences) Lu, Li-Gong (Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences) Li, Jia-Ping (Department of Interventional Oncology, The First Affiliate Hospital, Sun Yat-Sen University) |
1 | Yang JJ, Chen HJ, Yan HH, et al (2013). Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer, 79, 33-9. DOI ScienceOn |
2 | Yau T, Chan P, NG KK, et al (2009). Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer, 115, 428-36. DOI ScienceOn |
3 | Pop O, Pirvu A, Toffart AC, Moro-Sibilot D (2012). Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol, 7, 1-2. DOI |
4 | Miyahara K, Nouso K, Morimoto Y, et al (2013). Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatol Res, 44, 296-301 |
5 | Park JW, Koh YH, Kim HB, et al (2012). Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol, 56, 1336-42. DOI ScienceOn |
6 | Pinter M, Sieghart W, Graziadei I, et al (2009). Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist, 14, 70-6. DOI ScienceOn |
7 | Stock P, Monga D, Tan X, et al (2007). Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther, 6, 1932-41. |
8 | Strumberg D (2005). Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today, 41, 773-84. DOI ScienceOn |
9 | Wang Z, Wu Xl, Zeng WZ, et al (2013). Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 691-4. 과학기술학회마을 DOI ScienceOn |
10 | Wilhelm S, Carter C, Lynch M, et al (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5, 835-44. DOI ScienceOn |
11 | Worns MA, Weinmann A, Pfingst K, et al (2009). Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol, 43, 489-95. DOI ScienceOn |
12 | El-Serag HB, Rudolph Kl (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76. DOI ScienceOn |
13 | Chung YH, Han G, Yoon JH, et al (2013). Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization). with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer, 132, 2448-58. DOI ScienceOn |
14 | Dufour JF, Hoppe H, Heim MH, et al (2010). Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist, 15, 1198-204. DOI |
15 | Gedaly R, Angulo P, Hundley J, et al (2010). PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res, 30, 4951-8. |
16 | Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38. DOI ScienceOn |
17 | Huynh H, Ngo VC, Koong HN, et al (2009). Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med, 13, 2673-83. DOI ScienceOn |
18 | Huynh H, Nguyen TT, Chow KH, et al (2003). Over-expression of the mitogen-activated protein kinase (MAPK). kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol, 3, 19. DOI ScienceOn |
19 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
20 | Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med, 359, 378-90. DOI ScienceOn |
21 | Bruix J, Sherman M (2011b). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. DOI ScienceOn |
22 | Avila MA, Berasain C, Sangro B, Prieto J (2006). New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-84. DOI ScienceOn |
23 | Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9. 과학기술학회마을 DOI ScienceOn |
24 | Bruix J, Sherman M (2011a). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. DOI ScienceOn |
25 | Carlomagno F, Anaganti S, Guida T, et al (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98, 326-34. DOI ScienceOn |
26 | Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. DOI ScienceOn |
27 | Chaft JE, Oxnard GR, Sima CS, et al (2011). Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res, 17, 6298-303. DOI |
28 | Chen HJ, Yan HH, Yang JJ, et al (2013). Disease flare after egfr tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer. Pathol Oncol Res, 19, 833-8. DOI ScienceOn |
29 | Cheng Al, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10, 25-34. DOI ScienceOn |